The Spanish Agency for Medicines and Health Products (Aemps) reported on Wednesday the withdrawal from the market of all units distributed from two batches of Cafinitrine, used to treat and prevent angina, and its return to the laboratory through the usual channels due to an out-of-specification result in the content of the active ingredient nitroglycerin, A quality defect that does not pose a "serious or life-threatening risk" to the patient.
This was explained in a statement in which he specified that the batches affected by this defect are T009 and T010, both with an expiration date of August 31, 2025, of Cafinitrina sublingual coated tablets, in its presentation of 20 tablets, manufactured and marketed by Kern Pharma.
Cafinitrin belongs to the group of drugs called vasodilators used in heart disease, which increase the flow of blood to the heart and improve its performance when there is less risk in the coronary arteries.
According to the package leaflet, the drug is administered under the tongue to urgently treat acute attacks of angina, which consist of the sudden onset of pain or tightness in the chest, although it can be felt in the neck or arm, due to the lack of irrigation in the coronary arteries.
Also, to prevent angina pain when you are going to undertake a physical activity or situation that may trigger such pain.
- Medicine
According to the criteria of The Trust Project
Learn more